Editas Medicine - EDIT Stock Forecast, Price & News

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 2 sell ratings, 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View EDIT analyst ratings or view top-rated stocks.

15 brokers have issued twelve-month price targets for Editas Medicine's stock. Their EDIT share price forecasts range from $7.00 to $36.00. On average, they predict the company's share price to reach $16.73 in the next year. This suggests a possible upside of 44.1% from the stock's current price.
View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts.

Editas Medicine's stock was trading at $8.87 at the start of the year. Since then, EDIT shares have increased by 30.9% and is now trading at $11.61.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our EDIT earnings forecast.

Editas Medicine, Inc. (NASDAQ:EDIT) posted its quarterly earnings results on Monday, November, 8th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.24. The business earned $6.20 million during the quarter, compared to the consensus estimate of $4.92 million. Editas Medicine had a negative net margin of 784.32% and a negative trailing twelve-month return on equity of 41.33%. The company's revenue for the quarter was down 90.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.12 earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Editas Medicine's stock is owned by many different retail and institutional investors. Top institutional shareholders include Exchange Traded Concepts LLC (0.13%), Green Alpha Advisors LLC (0.09%), McGuire Investment Group LLC (0.02%), ProShare Advisors LLC (0.02%), Elmwood Wealth Management Inc. (0.02%) and Sigma Planning Corp (0.02%). Insiders that own company stock include Bruce Eaton, Charles Albright, Cynthia Collins, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends.

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EDIT stock can currently be purchased for approximately $11.61.

Editas Medicine (NASDAQ:EDIT) has a market capitalization of $798.30 million and generates $25.54 million in revenue each year. The company earns $-192,500,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis.

The company employs 264 workers across the globe.

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for the company is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com.